Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05188170 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later across 2 updates Jul 2026 → Dec 2026
See other at-risk trials from Stanford University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 2026 to Dec 2026
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Primary completion pushed from Jul 2026 to Sep 2026v11
  3. Eligibility criteria expanded, about 158 wordsv10
  4. Primary completion date: Jul 2025 to Jul 2026
    • Collaborators expanded, about 14 words
    v9
  5. 2 versions Re-verified since Jan 10, 2024, no change to tracked fieldsv7-v8
Show 5 earlier versionsHide 5 earlier versions
  1. Site contact updatedv6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 1, 2022 to Nov 21, 2022
    • Site details revised
    v5
  3. Start date: Jul 2022 to Nov 1, 2022
    • Site details revised
    v4
  4. Primary completion date: Jul 2022 to Jul 2025
    • Study completion date: Dec 2025 to Dec 2026
    • Eligibility criteria expanded, about 2 words
    • Study title shortened, about 4 words
    v3
  5. Study completion date: Jan 2023 to Dec 2025v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.
Trial Details
NCT Number NCT05188170
Lead Sponsor Stanford University
Collaborators: The Leukemia and Lymphoma Society, Pediatric Cancer Research Foundation (PCRF), CURE Childhood Cancer, Inc.
Conditions
(from sponsor)		 Acute Myeloid Leukemia (AML)
Related terms Leukemia, Myeloid, Acute
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov